Oral obesity treatments Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:00
Jan 25
Jan 25
Healthcare money flows to obesity and bispecifics.
At the JP Morgan Healthcare Conference, big M&A was absent but regulatory uncertainty eased, and licensing or technology-transfer money concentrated in bispecific antibodies, blood-brain barrier shuttles, and oral obesity. The speaker says the next cycle is focused on next-generation immuno-oncology, CNS, oral obesity, medical devices, and healthcare AI, making these areas worth remembering.
MED
About Oral obesity treatments Investor Commentary
Across the available history and selected sources, Buzzberg tracks Oral obesity treatments across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Choi Chang-gyu.